Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin
GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a Clinical Use Patent for arfolitixorin in the United States. The patent expires in 2038 and is the second patent in a series of clinical patent applications for arfolitixorin to be granted. The patent covers a dose regimen for treating solid tumors, such as colorectal, stomach, breast and liver cancer.The now granted patent, US 10,328,079, includes a dose regimen involving two or more injections of arfolitixorin in combination with 5-fluorouracil (5-FU). These two